FDA PMA FDA Class 3 Approved 🇺🇸 United States

Hybrid Stent Graft, Thoracic Aortic Lesion Treatment

PMA: P210006 · Supplement: S017 · Decision Apr 20, 2026
Classifications
1
FEI Numbers
0
Registration Numbers
0

Basic Information

Device Name
Hybrid Stent Graft, Thoracic Aortic Lesion Treatment
Trade Name
Thoraflex™ Hybrid
PMA Number
P210006
Supplement Number
S017
Device Class
FDA Class 3
Product Code
QSK
Generic Name
Hybrid stent graft, thoracic aortic lesion treatment
Medical Specialty
Unknown
Advisory Committee
Cardiovascular
Decision
Approved
Decision Code
APPR
Decision Date
April 20, 2026
Date Received
January 20, 2026
Supplement Type
Real-Time Process
Supplement Reason
Labeling Change - Indications/instructions/shelf life/tradename
Expedited Review
N

Advisory Committee Statement

Approval for extension of shelf-life to 3-years

Classifications

This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

Product Code Device Name
QSK Hybrid Stent Graft, Thoracic Aortic Lesion Treatment